Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FNCHNASDAQ:INDPNYSE:JATTNASDAQ:MIRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFNCHFinch Therapeutics Group$13.75+6.8%$13.11$1.10▼$15.85$22.08M1.252,186 shs402 shsINDPIndaptus Therapeutics$0.32-4.2%$0.42$0.31▼$2.70$5.21M1.31220,303 shs142,253 shsJATTJATT Acquisition$1.22-3.2%$1.21$7.80▼$12.38$21.05MN/A41,322 shs391,454 shsMIRAMIRA Pharmaceuticals$1.21-2.4%$1.16$0.51▼$5.01$20.47M1.962.20 million shs79,484 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFNCHFinch Therapeutics Group+6.75%+1.35%+5.36%+0.73%+926.12%INDPIndaptus Therapeutics-4.22%-5.39%-23.32%-59.66%-86.58%JATTJATT Acquisition-3.17%+3.39%+0.83%-4.69%-68.15%MIRAMIRA Pharmaceuticals-2.42%-13.57%-9.02%+2.54%+63.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFNCHFinch Therapeutics Group0.3434 of 5 stars0.03.00.00.00.01.70.6INDPIndaptus Therapeutics2.8582 of 5 stars3.52.00.00.03.01.71.3JATTJATT AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AMIRAMIRA Pharmaceuticals3.3237 of 5 stars3.75.00.00.04.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFNCHFinch Therapeutics Group 0.00N/AN/AN/AINDPIndaptus Therapeutics 3.00Buy$8.502,517.00% UpsideJATTJATT Acquisition 0.00N/AN/AN/AMIRAMIRA Pharmaceuticals 3.33Buy$14.001,057.02% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFNCHFinch Therapeutics Group$110K200.75N/AN/A$14.25 per share0.96INDPIndaptus TherapeuticsN/AN/AN/AN/A$1.44 per shareN/AJATTJATT AcquisitionN/AN/A$0.05 per share27.08($0.53) per shareN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.30 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/AINDPIndaptus Therapeutics-$15.42M-$1.49N/AN/AN/AN/A-177.27%-141.06%8/11/2025 (Estimated)JATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/AMIRAMIRA Pharmaceuticals-$11.98M-$0.51N/AN/AN/AN/A-337.44%-280.58%8/12/2025 (Estimated)Latest INDP, MIRA, FNCH, and JATT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025INDPIndaptus Therapeutics-$0.41-$0.32+$0.09-$0.32N/AN/A5/14/2025Q1 2025MIRAMIRA Pharmaceuticals-$0.15-$0.11+$0.04-$0.11N/AN/A3/28/2025Q4 2024MIRAMIRA Pharmaceuticals-$0.29-$0.15+$0.14-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFNCHFinch Therapeutics GroupN/A3.873.87INDPIndaptus TherapeuticsN/A3.423.42JATTJATT AcquisitionN/A0.150.15MIRAMIRA PharmaceuticalsN/A6.116.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFNCHFinch Therapeutics Group21.77%INDPIndaptus Therapeutics7.06%JATTJATT Acquisition47.97%MIRAMIRA Pharmaceuticals35.16%Insider OwnershipCompanyInsider OwnershipFNCHFinch Therapeutics Group44.90%INDPIndaptus Therapeutics20.60%JATTJATT Acquisition20.00%MIRAMIRA Pharmaceuticals6.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataINDPIndaptus Therapeutics616.03 million9.96 millionNot OptionableJATTJATT Acquisition317.25 million13.80 millionNot OptionableMIRAMIRA Pharmaceuticals216.92 million15.46 millionNot OptionableINDP, MIRA, FNCH, and JATT HeadlinesRecent News About These CompaniesVisionstate Launches MIRA to Digitize Facility Inspections and Expand SaaS PlatformJune 5, 2025 | thenewswire.comMIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical ProgramMay 28, 2025 | accessnewswire.comMIRA Pharmaceuticals Appoints New Chief Financial OfficerMay 21, 2025 | tipranks.comMIRA Releases Financials as Research ContinuesMay 15, 2025 | finance.yahoo.comMIRA Pharmaceuticals board approves SKNY Pharmaceuticals acquisition; combined value tops $60MMay 9, 2025 | msn.comMIRA Pharma Stock Soars To 2-Month High On $60M SKNY Deal: Retail Sentiment StrongMay 9, 2025 | msn.comMIRA Pharmaceuticals Acquires SKNY Pharmaceuticals for $60MMay 8, 2025 | tipranks.comMIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent ReviewMay 8, 2025 | accessnewswire.comMIRA Sets Up Success With Stellar Safety ResultsMay 7, 2025 | msn.comMIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked NeurotoxicityMay 6, 2025 | accessnewswire.comMira Pharmaceuticals reports in vitro drug release data for topical Ketamir-2April 25, 2025 | markets.businessinsider.comMIRA Pain Treatment Expands Market Size PotentialApril 23, 2025 | msn.comMIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track DesignationApril 23, 2025 | accessnewswire.comPharmaceutical Stock Jumps After Key Trial FindingsApril 17, 2025 | msn.comMira Pharmaceuticals announces results for Ketamir-2 in diabetic neuropathyApril 17, 2025 | markets.businessinsider.comMira Pharma Leads Healthcare Buzz Surge On Promising Oral Ketamine Analog Preclinical TrialApril 17, 2025 | msn.comMIRA Continues Positive Testing RunApril 16, 2025 | msn.comEXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal StudyApril 16, 2025 | finance.yahoo.comMIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I CompletionApril 16, 2025 | accessnewswire.comMira Pharmaceuticals enrolls first subjects in Phase 1 trial of Ketamir-2April 2, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINDP, MIRA, FNCH, and JATT Company DescriptionsFinch Therapeutics Group NASDAQ:FNCH$13.75 +0.87 (+6.75%) As of 06/13/2025 03:35 PM EasternFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Indaptus Therapeutics NASDAQ:INDP$0.32 -0.01 (-4.22%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.33 +0.00 (+0.68%) As of 06/13/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.JATT Acquisition NYSE:JATT$1.22 -0.04 (-3.17%) As of 06/12/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.MIRA Pharmaceuticals NASDAQ:MIRA$1.21 -0.03 (-2.50%) As of 06/13/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
